Calavo Growers (CVGW) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
13 Jun, 2025Executive summary
Net sales increased 12% year-over-year to $179.6 million, driven by strong avocado demand and pricing, despite supply disruptions from Mexico.
Gross profit declined 9% to $20.1 million, with margin pressure in both Grown and Prepared segments.
Net loss attributable to Calavo was $0.7 million, compared to net income of $6.6 million in the prior year, mainly due to discontinued operations and a $9.3 million goodwill impairment.
Sale of the Fresh Cut business completed in August 2024 for $83 million, with proceeds used to retire all remaining debt.
Quarterly dividend doubled to $0.20 per share, reflecting confidence in core business and improved financial performance.
Financial highlights
Net sales for the nine months ended July 31, 2024 rose 9% to $491.6 million.
Gross profit for the nine months increased 7% to $51.5 million.
Adjusted EBITDA from continuing operations was $13.5 million for the quarter, up from $13.0 million a year ago.
Adjusted net income from continuing operations was $10.2 million for the quarter, up from $7.7 million in the prior year.
Diluted EPS from continuing operations was $0.30 for the quarter, down from $0.48 last year; adjusted EPS was $0.57.
Outlook and guidance
Proceeds from the Fresh Cut sale are expected to support shareholder returns and investment in core business growth.
Management expects continued momentum and improvement in the Prepared segment in Q4 as input costs recede and new guacamole products launch.
The company believes liquidity and cash flow are sufficient to meet foreseeable capital and operational needs.
Latest events from Calavo Growers
- Shareholders to vote on a merger offering Calavo holders cash and Mission Produce stock at a premium.CVGW
Proxy filing20 Mar 2026 - Net sales fell 21%, but Prepared segment grew 20% and merger progress continued.CVGW
Q1 202612 Mar 2026 - Deal creates a top produce platform with $25M in synergies, closing by August 2026.CVGW
M&A announcement15 Jan 2026 - Net income soared 192% year-over-year; merger with Mission Produce targets $25M synergies.CVGW
Q4 202514 Jan 2026 - Annual meeting covers director elections, auditor ratification, compensation, and equity plan extension.CVGW
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and equity plan changes up for vote at annual meeting.CVGW
Proxy Filing1 Dec 2025 - Annual meeting set for April 23, 2025, with key proposals and voting details in proxy materials.CVGW
Proxy Filing1 Dec 2025 - Prepared segment growth and legal resolutions drove improved adjusted results despite FDA-related costs.CVGW
Q3 20259 Sep 2025 - Q2 net sales up 16.5% with margin gains; Fresh Cut sale and FCPA probe remain key themes.CVGW
Q2 202413 Jun 2025